Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14134716 | 0.98 | ALDH1A1 (0.32) | ALDH1A1HRH3 | |
| SCHEMBL14134715 | 0.98 | ALDH1A1 (0.32) | ALDH1A1HRH3 | |
| SCHEMBL7890530 | 0.92 | ALDH1A1 (0.34) | ALDH1A1HRH3MAPTMAPK1CASP3 | |
| SCHEMBL21162650 | 0.85 | HRH3 (0.38) | HRH3MAPT | |
| SCHEMBL4482423 | 0.81 | — | — | |
| SCHEMBL10028946 | 0.81 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL4609242 | 0.81 | ALDH1A1 (0.41) | ALDH1A1MAPTMAPK1CASP3BLM | |
| SCHEMBL18776667 | 0.80 | HRH3 (0.36) | HRH3 | |
| SCHEMBL20206379 | 0.79 | HRH3 (0.38) | ALDH1A1HRH3 | |
| SCHEMBL24621825 | 0.79 | ALDH1A1 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180147291-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2018-05-31 | — | — | US | disclosed |
| US-9878047-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170247340-A1 | Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof | LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY | 2017-08-31 | — | — | US | disclosed |
| US-20160263234-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9309283-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9067928-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-8951998-B2 | Quinoxaline-containing compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8951998-B2 | Quinoxaline-containing compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140105921-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | ONYX THERAPEUTICS, INC. | 2014-04-17 | — | — | US | disclosed |
| US-8518970-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8324155-B2 | Quinoxaline-containing compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2012-07-19 | — | — | US | disclosed |
| US-8114893-B2 | Compounds and methods of use | GENENTECH, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140105921-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | PREP, VIP, PEPD | ALDH1A1 1285/4885HRH3 3376/4885MAPT 3880/4885 |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BCL2A1, BAX, BCL2 | ALDH1A1 3017/4885HRH3 3090/4885MAPT 4846/4885 |
| US-20160263234-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, VIP, PEPD | ALDH1A1 1285/4885HRH3 3376/4885MAPT 3880/4885 |
| US-20180147291-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, VIP, PEPD | ALDH1A1 1285/4885HRH3 3376/4885MAPT 3880/4885 |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | ALDH1A1 3814/4885HRH3 2959/4885MAPT 4858/4885 |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | ALDH1A1 3814/4885HRH3 2959/4885MAPT 4858/4885 |
| US-20170247340-A1 | Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof | ACP1, PTPRCAP, PTPA | ALDH1A1 2399/4885HRH3 4805/4885MAPT 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.